Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) EBIT (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of EBIT data on record, last reported at -$17.8 million in Q1 2026.

  • On a quarterly basis, EBIT fell 22.22% to -$17.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$55.2 million, a 43.78% decrease, with the full-year FY2025 number at -$52.0 million, down 81.8% from a year prior.
  • EBIT reached -$17.8 million in Q1 2026 per IKT's latest filing, down from -$13.8 million in the prior quarter.
  • Over the last five years, EBIT for IKT hit a ceiling of -$4.3 million in Q4 2022 and a floor of -$17.8 million in Q1 2026.
  • A 5-year average of -$8.0 million and a median of -$5.1 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: rose 18.57% in 2024, then plummeted 205.25% in 2025.
  • Tracing IKT's EBIT over 5 years: stood at -$4.3 million in 2022, then dropped by 1.58% to -$4.4 million in 2023, then plummeted by 193.6% to -$12.9 million in 2024, then fell by 6.55% to -$13.8 million in 2025, then decreased by 29.52% to -$17.8 million in 2026.
  • Business Quant data shows EBIT for IKT at -$17.8 million in Q1 2026, -$13.8 million in Q4 2025, and -$12.8 million in Q3 2025.